Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-12
2011-04-12
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359100
Reexamination Certificate
active
07923465
ABSTRACT:
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).
REFERENCES:
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5081122 (1992-01-01), Ward
patent: 5112820 (1992-05-01), Ward
patent: 5217523 (1993-06-01), Ditrich et al.
patent: 5292736 (1994-03-01), Kumar et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6355631 (2002-03-01), Achard et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 7244757 (2007-07-01), Chen et al.
patent: 7425630 (2008-09-01), Gharbaoui et al.
patent: 7456177 (2008-11-01), Allen et al.
patent: 2003/0162824 (2003-08-01), Krul
patent: 2004/0220170 (2004-11-01), Atkinson et al.
patent: 2005/0020564 (2005-01-01), Atkinson et al.
patent: 2005/0020830 (2005-01-01), Allen et al.
patent: 2005/0222239 (2005-10-01), Chen et al.
patent: 2005/0261281 (2005-11-01), Lazzari et al.
patent: 2006/0154940 (2006-07-01), Gharbaoui et al.
patent: 2007/0149406 (2007-06-01), Bastiaans et al.
patent: 1183409 (1998-06-01), None
patent: 10219294 (2003-11-01), None
patent: 0576357 (1993-12-01), None
patent: 0658546 (1995-06-01), None
patent: 0699438 (1996-03-01), None
patent: 1975168 (2008-10-01), None
patent: 2665898 (1992-02-01), None
patent: WO-95/15316 (1995-06-01), None
patent: WO-97/11704 (1997-04-01), None
patent: WO-9729079 (1997-08-01), None
patent: WO-98/31227 (1998-07-01), None
patent: WO-9837061 (1998-08-01), None
patent: WO-98/41519 (1998-09-01), None
patent: WO-98/43635 (1998-10-01), None
patent: WO-98/43636 (1998-10-01), None
patent: WO-9902499 (1999-01-01), None
patent: WO-0010967 (2000-03-01), None
patent: WO-0010968 (2000-03-01), None
patent: WO-00/39108 (2000-07-01), None
patent: WO-00/69849 (2000-11-01), None
patent: 01/32629 (2001-05-01), None
patent: 01/32663 (2001-05-01), None
patent: WO-01/40195 (2001-06-01), None
patent: 01/58869 (2001-08-01), None
patent: WO-01/57024 (2001-08-01), None
patent: WO-0164632 (2001-09-01), None
patent: WO-0164633 (2001-09-01), None
patent: WO-0164634 (2001-09-01), None
patent: WO-0170700 (2001-09-01), None
patent: WO-02/04424 (2002-01-01), None
patent: WO-02076949 (2002-10-01), None
patent: WO-03/020217 (2003-03-01), None
patent: WO-03026647 (2003-04-01), None
patent: WO-03026648 (2003-04-01), None
patent: WO-03027069 (2003-04-01), None
patent: WO-03027076 (2003-04-01), None
patent: WO-03027114 (2003-04-01), None
patent: WO-03077847 (2003-09-01), None
patent: WO-03/088968 (2003-10-01), None
patent: WO-2004013120 (2004-02-01), None
patent: WO-2004026301 (2004-04-01), None
patent: WO-2004058145 (2004-07-01), None
patent: WO-2004058744 (2004-07-01), None
patent: WO-2004069837 (2004-08-01), None
patent: WO-2004/078261 (2004-09-01), None
patent: WO-2004096763 (2004-11-01), None
patent: WO-2005/000820 (2005-01-01), None
patent: WO-2005/063020 (2005-07-01), None
patent: WO-2005/063737 (2005-07-01), None
patent: WO-2006/015860 (2006-02-01), None
patent: 2006/030124 (2006-03-01), None
patent: WO-2006/129178 (2006-12-01), None
patent: WO-2007/009701 (2007-01-01), None
patent: WO-2007/022502 (2007-02-01), None
patent: WO-2007/025892 (2007-03-01), None
patent: WO-2008/017932 (2008-02-01), None
patent: WO-2008/075013 (2008-06-01), None
patent: WO-2008/080541 (2008-07-01), None
patent: WO-2008/080542 (2008-07-01), None
Watson et al., 1995, CAS: 124:104533.
Nagai et al., 1980, CAS: 92:181074.
Egg et al., 1969, CAS: 71: 101768.
Ruiu, S., et al., Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1Cannabinoid Receptor, Journal of Pharmacology and Experimental Therapeutics, 306(1):363-370, 2003.
Vicentini, C. et al., Synthetic Pyrazole Derivatives as Growth Inhibitors of Some Phytopathogenic Fungi, Journal of Agricultural and Food Chemistry, 55(25):10331-10338, 2007.
Thomas, B. et al., Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities, Bioorganic & Medicinal Chemistry, 13(18):5463-5474, 2005.
Mussinu, J-M, et al., Tricyclic Pyrazoles. Part 1: Synthesis and Biological Evaluation of Novel 1,4-Dihydroindeno[1,2-c]pyrazol-based Ligands for CB1 and CB2 Cannabinoid Receptors, Bioorganic & Medicinal Chemistry, 11:521-263, 2003.
Nagai, Shin-Ichi, et al., “Synthesis of Pyrazolone Derivatives. XXXV.1) Synthetic and Pharmacological Studies on Some (4S, 7R)-4,7-Methano-1H-indazoles2),” Chem. Pharm. Bull., vol. 27, No. 8, 1979, p. 1764-1770.
Egg, H. & K. zur Nedded, “p-Toluol-und Methansulfonamide Substituierter Pyrazolcarbonsauren,” Monatshefte Fur Chemie, vol. 100, 1969, p. 1256-1259.
Database Crossfire, Beilstein Institutr Zur Foerderung der Wissenschaften, Frankfurt Am Main, DE, 1982, Database Accession No. 16616 (BRN).
Wallach, O. & A. Steindorff, “Zur Kenntnis der Terpene und der atherischen Ole; I. Uber die Umwandlung Cyklischer Ketone in Pyrazolbasen,” Justus Liebigs Ann. Chem., vol. 329, 1903, p. 109-133.
Jonathan A. Waitman, M.D. and Louis J. Aronne, M.D., “Pharmacotherapy of Obesity”, Obesity Management, Jan. 2005, pp. 15-20, Dept. of Medicine at Weill-Cornell University Medical College, New York, NY.
Jason E. Gallate, Tanya Saharov, Paul E. Mallet, Iain S. McGregor, “Increased Motivation for Beer in Rats Following Administration of a Cannabinoid CB1 Receptor Agonist”, European Journal of Pharmacology, vol. 370 (1999), pp. 233-240.
Claire M. Williams, Tim C. Kirkham, “Observational Analysis of Feeding Induced by D9-THC and Anandamide”, Physiology & Behavior, vol. 76 (2002) pp. 241-250.
Jason E. Gallate, Iain S. McGregor, “The Motivation for Beer in Rats: Effects of Ritanserin, Naloxone and SR 141716”, Psychopharmacology (1992) vol. 142, pp. 302-308.
Michele Arnone, Jeanne Maruani, Frederique Chaperon, Marie-Helene Thiebot, Martine Poncelet, Philippe Soubrie, Gerard Le Fur, “Selective Inhibition of Sucrose and Ethanol Intake by SR 141716, An Antagonist of Central Cannabinoid (CB1) Receptors”, Psychopharmacology (1997) vol. 132, pp. 104-106.
Jared Ehrhart, Demian Obregon, Takashi Mori, Huayan Hou, Nan Sun, Yun Bai, Thomas Klein, Francisco Fernandez, Jun Dan and R. Douglas Shytle, “Stimulation of Cannabinoid Receptor 2 (CB2) Suppresses Microglial Activation”, Journal of Neuroinflammation, Dec. 12, 2005, pp. 1-13.
B.L. Hungund and B.S. Basavarajappa, “Are Anandamide and Cannabinoid Receptors Involved in Ethanol Tolerance? A Review of the Evidence”, Alcohol & Alcoholism, (2000) vol. 35 No. 2, pp. 126-133.
Balasubramanian Gopalan
Gullapalli Srinivas
Joshi Neelima Khairatkar
Muthuppalaniappan Meyyappan
Narayanan Shridhar
Blank Rome LLP
Glenmark Pharmaceuticals S.A.
Shiao Rei-tsang
LandOfFree
Cannabinoid receptor ligands, pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor ligands, pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor ligands, pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659219